{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:52:09Z","timestamp":1789080729229,"version":"build-2803163510"},"reference-count":63,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>(1) Background: This study aimed to examine the difference in efficacy and toxicity of involved-field (IFRT) and involved-site radiotherapy (ISRT) fields in infradiaphragmal aggressive non-Hodgkin lymphoma patients. (2) Methods: In total, 140 patients with infradiaphragmal lymphoma treated between 2003 and 2020 were retrospectively evaluated. There were 69 patients (49%) treated with IFRT, and 71 (51%) patients treated with ISRT. The median dose in the IFRT group was 36 Gy, (range 4\u201350.4 Gy), and in the ISRT group, it was 30 Gy (range 4\u201348 Gy). (3) Results: The median follow-up in the IFRT group was 133 months (95% CI 109\u2013158), and in the ISRT group, it was 48 months (95% CI 39\u201357). In the IFRT group, locoregional control was 67%, and in the ISRT group, 73%. The 2- and 5-year overall survival (OS) in the IFRT and ISRT groups were 79% and 69% vs. 80% and 70%, respectively (p = 0.711). The 2- and 5-year event-free survival (EFS) in the IFRT and ISRT groups were 73% and 68% vs. 77% and 70%, respectively (p = 0.575). Acute side effects occurred in 43 (31%) patients, which is more frequent in the IFRT group, 34 (39%) patients, than in the ISRT group, 9 (13%) patients, p &gt; 0.01. Late toxicities occurred more often in the IFRT group of patients, (10\/53) 19%, than in the ISRT group of patients, (2\/37) 5%, (p = 0.026). (4) Conclusions: By reducing the radiotherapy volume and the doses in the treatment of infradiaphragmatic fields, treatment with significantly fewer acute and long-term side effects is possible. At the same time, efficiency and local disease control are not compromised.<\/jats:p>","DOI":"10.3390\/cancers16030649","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T05:36:43Z","timestamp":1707197803000},"page":"649","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins\u2019s Lymphoma Patients\u2014A Single Centre Experience"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2840-5734","authenticated-orcid":false,"given":"Lea","family":"Galunic Bilic","sequence":"first","affiliation":[{"name":"Department of Oncology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedor","family":"Santek","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdravko","family":"Mitrovic","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"},{"name":"Division of Haematology, Department of Internal Medicine, Clinical Hospital Dubrava, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Basic-Kinda","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dino","family":"Dujmovic","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijo","family":"Vodanovic","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5234-9464","authenticated-orcid":false,"given":"Inga","family":"Mandac Smoljanovic","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Clinical Hospital Merkur, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slobodanka","family":"Ostojic Kolonic","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"},{"name":"Division of Haematology, Department of Internal Medicine, Clinical Hospital Merkur, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruzica","family":"Galunic Cicak","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Aurer","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"},{"name":"Division of Haematology, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukaemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/asheducation-2004.1.221","article-title":"Diffuse aggressive lymphoma","volume":"2004","author":"Fisher","year":"2004","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0360-3016(94)90352-2","article-title":"Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma","volume":"30","author":"Aviles","year":"1994","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000012104","article-title":"Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III\u2013IV diffuse large B cell lymphomas","volume":"58","author":"Ferreri","year":"2000","journal-title":"Oncology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1200\/JCO.2015.61.7654","article-title":"Treatment selection and survival outcomes in early-stage diffuse-large B-cell lymphoma: Do we still need consolidative radiotherapy?","volume":"33","author":"Vargo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1200\/JCO.2009.27.3441","article-title":"Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy","volume":"28","author":"Phan","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1200\/JOP.18.00519","article-title":"Times Not to Forget Radiotherapy When Treating Patients with Lymphoma","volume":"15","author":"Enke","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/02841860310014435","article-title":"A systematic overview of radiation therapy effects in non-Hodgkin\u2019s lymphoma","volume":"42","author":"Gustavsson","year":"2003","journal-title":"Acta Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma-Target Definition and Dose Guidelines from the International Lymphoma Oncology Group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20150409","DOI":"10.1259\/bjr.20150409","article-title":"Evolution of radiation techniques in the treatment of mediastinal lymphoma: From 3D conformal radiotherapy (3DCRT) to intensity-modulated RT (IMRT) using helical tomotherapy (HT): A single-centre experience and review of the literature","volume":"89","author":"Besson","year":"2016","journal-title":"Br. J. Radiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10147-013-0556-3","article-title":"Evolution of the techniques of radiation therapy in the management of lymphoma","volume":"18","author":"Hoppe","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clon.2012.07.011","article-title":"Recommendations for the use of radiotherapy in nodal lymphoma","volume":"25","author":"Hoskin","year":"2013","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ijrobp.2009.07.1706","article-title":"Involved lesion radiation therapy after chemotherapy in limited stage head and neck diffuse large B cell lymphoma","volume":"78","author":"Yu","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2013.07.013","article-title":"Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin\u2019s lymphoma","volume":"109","author":"Verhappen","year":"2013","journal-title":"Radiother. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20210469","DOI":"10.1259\/bjr.20210469","article-title":"Harnessing benefit of highly conformal RT techniques for lymphoma patients","volume":"94","author":"Petersen","year":"2021","journal-title":"Br. J. Radiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymhoma: Concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/COAYA.S70370","article-title":"Involved site radiation therapy for the treatment of early-stage Hodgkin lymphoma in adolescents and young adults","volume":"5","author":"Portlock","year":"2015","journal-title":"Clin. Oncol. Adolesc. Young Adults"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","unstructured":"ICRU (1993). Prescribing, Recording and Reporting photon-beam therapy (report 50). J. ICRU, 50, 26."},{"key":"ref_21","unstructured":"ICRU (1999). Prescribing, Recording and Reporting photon-beam therapy (report 62)\u2014Suppl to ICRU Report 50. J. ICRU, 32, 9\u201352."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jicru_ndq002","article-title":"Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT) (report 83)","volume":"10","author":"DeLuca","year":"2010","journal-title":"J. ICRU"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0167-8140(85)80086-4","article-title":"Role of radiation therapy in localized non-Hodgkin\u2019s lymphoma","volume":"4","author":"Sutcliffe","year":"1985","journal-title":"Radiother. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1748-717X-7-100","article-title":"Radiotherapy dose-response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy","volume":"7","author":"Dorth","year":"2012","journal-title":"Radiat. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00066-016-0992-x","article-title":"Survival benefit by consolidating Radiotherapy in Patients with diffuse large B-Cell Lymphoma in Early Stages","volume":"192","author":"Elsayad","year":"2015","journal-title":"Strahlenther. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2004.06.088","article-title":"Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin\u2019s lymphoma: Eastern Cooperative Oncology Group study 1484","volume":"22","author":"Horning","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/cncr.29113","article-title":"Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project","volume":"121","author":"Dabaja","year":"2015","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/PPO.0000000000000453","article-title":"Radiotherapy for Non-Hodgkin Lymphomas","volume":"26","author":"Imber","year":"2020","journal-title":"Cancer J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"B84","DOI":"10.1007\/PL00022798","article-title":"Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL","volume":"80","author":"Nguyen","year":"2001","journal-title":"Ann. Hematol."},{"key":"ref_31","first-page":"1233","article-title":"Consolidation radiotherapy for advanced-stage aggressive B-cell non-Hodgkin lymphoma: A systematic review and meta-analysis","volume":"16","author":"Yap","year":"2017","journal-title":"EXCLI J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3324\/haematol.2020.249680","article-title":"Impact on survival through consolidation radiotherapy for diffuse large B-cell lymphoma: A comprehensive meta-analysis","volume":"106","author":"Berger","year":"2021","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12254-022-00803-y","article-title":"Radiotherapy update: Current role of radiotherapy in the treatment of lymphomas","volume":"16","author":"Waldstein","year":"2023","journal-title":"Memo"},{"key":"ref_34","unstructured":"(2023, September 18). Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: Field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejmp.2018.12.036","article-title":"Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin\u2019s disease","volume":"57","author":"Kourinou","year":"2019","journal-title":"Phys. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clon.2015.03.005","article-title":"Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks","volume":"27","author":"Murray","year":"2015","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"658358","DOI":"10.3389\/fonc.2021.658358","article-title":"Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients\u2014An Analysis of GHSG HD14- and HD17-Patients","volume":"11","author":"Rosenbrock","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00066-019-01460-7","article-title":"Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: Clinical outcome and dosimetric comparison","volume":"195","author":"Bougatf","year":"2019","journal-title":"Strahlenther. Onkol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/0284186X.2016.1197422","article-title":"Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: Results from the proton collaborative group registry","volume":"55","author":"Hoppe","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13014-018-1066-2","article-title":"Proton versus photon deep inspiration breath hold technique in patients with Hodgkin lymphoma and mediastinal radiation","volume":"13","author":"Baues","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/0284186X.2018.1512153","article-title":"Comparative treatment planning study for mediastinal Hodgkin\u2019s lymphoma: Impact on normal tissue dose using deep inspiration breath hold proton and photon therapy","volume":"58","author":"Edvardsson","year":"2019","journal-title":"Acta Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0161-5890(03)00080-4","article-title":"Abdominal irradiation after chemotherapy in Non-Hodgkin\u2019s Lymphoma: Review of 32 patients","volume":"39","author":"Brihi","year":"2003","journal-title":"Mol. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0360-3016(88)90343-4","article-title":"Complications from large field intermediate dose infradiaphragmatic radiation: An analysis of the patterns of care outcome studies for Hodgkin\u2019s disease and seminoma","volume":"15","author":"Coia","year":"1987","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1148\/radiology.192.2.8029434","article-title":"Non-Hodgkin\u2019s Lymphoma: Whole-abdomen Irradiation as an Adjuvant to Chemotherapy","volume":"192","author":"Valicenti","year":"1994","journal-title":"Radiology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11547-023-01615-8","article-title":"Efficacy and toxicity of infradiaphragmal radiotherapy fields in lymphoma patients: A single-centre experience","volume":"128","author":"Santek","year":"2023","journal-title":"Radiol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0167-8140(84)80044-4","article-title":"Radiation injuries of the gastrointestinal tract in Hodgkin\u2019s disease: The role of exploratory laparotomy and fractionation","volume":"2","author":"Fayolle","year":"1984","journal-title":"Radiother. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0167-8140(85)80041-4","article-title":"Intestinal complications of wide field abdominal irradiation for lymphoma","volume":"3","author":"Langlios","year":"1985","journal-title":"Radiother. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0360-3016(98)00034-0","article-title":"Long-term results of total abdominopelvic irradiation in non-Hodgkin\u2019s lymphomas after failure of chemotherapy","volume":"41","author":"Bourdin","year":"1998","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/aje\/kwn146","article-title":"Daily total physical activity level and total cancer risk in men and women: Results from a large-scale population-based cohort study in Japan","volume":"168","author":"Inoue","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s10897-016-9979-0","article-title":"Predispositions to Lymphoma: A Practical Review for Genetic Counselors","volume":"25","author":"Similuk","year":"2016","journal-title":"J. Genet. Couns."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0360-3016(97)00570-1","article-title":"Is there an increased risk of second primaries following prostate radiation?","volume":"41","author":"Movsas","year":"1998","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO;2-V","article-title":"Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery","volume":"88","author":"Brenner","year":"2000","journal-title":"Cancer"},{"key":"ref_54","first-page":"955","article-title":"Second cancers following radiation treatment for cervical cancer: An international collaboration among cancer registries","volume":"74","author":"Boice","year":"1985","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/jnci\/djm201","article-title":"Second cancers among 104,760 survivors of cervical cancer: Evaluation of long-term risk","volume":"99","author":"Chaturvedi","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijrobp.2011.04.013","article-title":"Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma","volume":"81","author":"Creutzberg","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ijrobp.2011.08.034","article-title":"Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer","volume":"83","author":"Zelefsky","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1200\/JCO.2006.10.5296","article-title":"Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer","volume":"25","author":"Gietema","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","article-title":"Proportion of second cancers attributable to radiotherapy treatment in adults: A cohort study in the US SEER cancer registries","volume":"12","author":"Curtis","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.radonc.2016.08.017","article-title":"Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: A systematic review and meta-analysis of population-based studies including 522,739 patients","volume":"121","author":"Grantzau","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.radonc.2015.10.022","article-title":"Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma","volume":"118","author":"Parikh","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.3346\/jkms.2016.31.S1.S75","article-title":"Evolving Clinical Cancer Radiotherapy: Concerns Regarding Normal Tissue Protection and Quality Assurance","volume":"31","author":"Choi","year":"2016","journal-title":"J. Korean Med. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ijrobp.2021.06.030","article-title":"Clinical Outcomes Confirm Conjecture: Modern Radiation Therapy Reduces the Risk of Late Toxicity in Survivors of Hodgkin Lymphoma","volume":"111","author":"Milgrom","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/3\/649\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:54:11Z","timestamp":1760104451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/3\/649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["cancers16030649"],"URL":"https:\/\/doi.org\/10.3390\/cancers16030649","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]}}}